In Vitro Intrinsic Clearance-Based Optimization of <i>N</i><sup>3</sup>-Phenylpyrazinones as Corticotropin-Releasing Factor-1 (CRF<sub>1</sub>) Receptor Antagonists
作者:Richard A. Hartz、Vijay T. Ahuja、Maria Rafalski、William D. Schmitz、Allison B. Brenner、Derek J. Denhart、Jonathan L. Ditta、Jeffrey A. Deskus、Eddy W. Yue、Argyrios G. Arvanitis、Snjezana Lelas、Yu-Wen Li、Thaddeus F. Molski、Harvey Wong、James E. Grace、Kimberley A. Lentz、Jianqing Li、Nicholas J. Lodge、Robert Zaczek、Andrew P. Combs、Richard E. Olson、Ronald J. Mattson、Joanne J. Bronson、John E. Macor
DOI:10.1021/jm900302q
日期:2009.7.23
identified as potent and orally active corticotropin-releasing factor-1 (CRF1) receptor antagonists. Selected compounds proved efficacious in an anxiety model in rats; however, pharmacokinetic properties were not optimal. In this article, we describe an in vitro intrinsic clearance-based approach to the optimization of pyrazinone-based CRF1 receptor antagonists wherein sites of metabolism were identified
一系列基于吡嗪酮的杂环被鉴定为有效的和口服活性的促肾上腺皮质激素释放因子1(CRF 1)受体拮抗剂。所选择的化合物在大鼠焦虑模型中证明是有效的。但是,药代动力学特性不是最佳的。在本文中,我们描述了一种基于体外固有清除率的方法,用于优化基于吡嗪酮的CRF 1受体拮抗剂,其中通过与人肝微粒体孵育来确定代谢位点。发现通过在代谢的主要位点掺入适当的取代基可以降低代谢速率。这导致发现化合物12x,高效能(IC 50 = 1.0 nM)和选择性CRF1种受体拮抗剂,在大鼠中具有良好的口服生物利用度(F = 52%),并且在大鼠的防御性戒断焦虑测试中具有疗效。